Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment
Syntara expands Phase 1b trial for SNT-9465, adding 10 participants, new blinded design and Sydney site; top-line data due Q1 2027 to back an IND.
Latest Stories — SECTOR DESK
LTR Pharma Final Phase II Report Confirms Fast Absorption for Spontan Intranasal Spray in Treating ED
LTR Pharma's Spontan intranasal ED spray peaks in 10 minutes, six-fold faster than oral vardenafil; Phase II data complete, paving US licensing talks.
Vitrafy Life Sciences Expands Platelet Cryopreservation Program With Versiti Blood Health
Vitrafy Life Sciences expands platelet cryopreservation with Versiti; 94.4% post-thaw recovery from USAISR, two free units, US device listing aimed FY2027.
INOVIQ Defines EXO-OC Commercialisation Path after Independent Review
INOVIQ maps a 12–18 month path to US LDT for EXO-OC after independent review; aims for H1 2028 lab validation amid sample-handling variability.
Singular Health Group Signs Deal for Florida’s First State-Funded Medical Imaging Repository
Singular Health inks Florida deal for state-funded 3DICOM imaging repository with FIU, signalling first infrastructure revenue and potential Medicaid blueprint.
Nexsen Enters into Molecular GBS Diagnostic Joint Venture with FlashDx Shenzhen
Nexsen to form a 50:50 GBS diagnostic JV with FlashDx Shenzhen, targeting FDA 510(k) and EU IVDR clearance and APAC market entry.
BCAL Diagnostic Commences Phased Australian Rollout of Avantect Multi-Cancer Blood Test
BCAL Diagnostics begins phased Australian rollout of Avantect Multi-Cancer blood test, expanding early detection across NSW, Victoria and beyond.
Genetic Signatures and Microba Life Sciences Set Commercial Terms for Merger
Genetic Signatures and Microba agree all-scrip merger; MAP holders to own ~67% of the combined group at 0.654 GSS per MAP share; GSS remains ASX-listed.
Nyrada Raises Fresh Capital to Fund Xolatryp Phase IIa And Pipeline Expansion
Nyrada raises A$12m via placement to fund Xolatryp Phase IIa PROTECT-MI and pipeline expansion; targets a further A$2m via SPP, with board participation.
Memphasys Secures Exclusive Distribution Agreement with INVIDO LAB for Felix System
Memphasys nets exclusive Felix System deal with INVIDO LAB in Czech Republic, Slovakia, Kazakhstan; €416k min purchases, unlocking recurring cartridge revenue.
AdAlta Validates Commercial Viability of IRO Manufacturing Strategy with Oribiotech Deal
AdAlta's IRO platform earns commercial validation as Oribiotech inks a 10-year, up to US$120m deal to manufacture a marketed cell therapy in APAC.
Prescient Therapeutics Hits Enrolment Threshold for PTX-100 Phase 2a Trial Review
Prescient Therapeutics hits enrolment milestone: PTX-100 Phase 2a reaches 20 evaluable patients; first Dose Optimisation Committee review in December 2026.